Genetic variations in detoxification enzymes and HIF-1α in Japanese patients with COPD

Clinical Respiratory Journal

Volumn 7, Issue 1, 2013, Pages 7-15

  Putra, Andika Chandra ^a   Tanimoto, Keiji ^a   Arifin, Marina ^a   Antariksa, Budhi ^b   Hiyama, Keiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

COPD; Detoxification; Genetic susceptibility; Hypoxia inducible factor 1; Polymorphism

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; ENZYME; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; INTRON; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; EPOXIDE HYDROLASES; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HEME OXYGENASE-1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; JAPAN; MALE; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84875659961     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00255.x     Document Type: Article

References (36)

1. Rabe KF, Hurd S, Anzueto A, etal. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532-55.
2. Fukuchi Y, Nishimura M, Ichinose M, etal. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9: 458-65.
3. Janson C. Phenotypes of obstructive lung disease. Clin Respir J. 2008;2(Suppl. 1): 88-91.
4. Mak JC. Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance. Int J Tuberc Lung Dis. 2008;12: 368-74.
5. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis. 2008;12: 361-7.
6. Hirvonen A. Gene-environment interactions in chronic pulmonary diseases. Mutat Res. 2009;667: 132-41.
7. Barnes PJ. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999;54: 245-52.
8. Boschetto P, Quintavalle S, Miotto D, Lo Cascio N, Zeni E, Mapp CE. Chronic obstructive pulmonary disease (COPD) and occupational exposures. J Occup Med Toxicol. 2006;1: 11.
9. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration. 2001;68: 4-19.
10. Miller MC 3rd, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett. 2001;120: 269-80.
11. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res. 2000;464: 65-76.
12. Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J. 2004;23: 818-24.
13. Calikoglu M, Tamer L, Ates Aras N, Karakas S, Ercan B. The association between polymorphic genotypes of glutathione S-transferases and COPD in the Turkish population. Biochem Genet. 2006;44: 307-19.
14. Yim JJ, Yoo CG, Lee CT, Kim YW, Han SK, Shim YS. Lack of association between glutathione S-transferase P1 polymorphism and COPD in Koreans. Lung. 2002;180: 119-25.
15. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997;6: 733-43.
16. Tuder RM, Yun JH, Bhunia A, Fijalkowska I. Hypoxia and chronic lung disease. J Mol Med. 2007;85: 1317-24.
17. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92: 5510-4.
18. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15: 678-85.
19. Tanimoto K, Yoshiga K, Eguchi H, etal. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24: 1779-83.
20. Yamakido M, Ishioka S, Hiyama K, Maeda A. Former poison gas workers and cancer: incidence and inhibition of tumor formation by treatment with biological response modifier N-CWS. Environ Health Perspect. 1996;104(Suppl. 3): 485-8.
21. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med. 2000;5: 49-53.
22. Budhi A, Hiyama K, Isobe T, Oshima Y, Hara H, Maeda H, Kohno N. Genetic susceptibility for emphysematous changes of the lung in Japanese. Int J Mol Med. 2003;11: 321-9.
23. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66: 187-95.
24. Wang SL, Lee H, Chen KW, Tsai KJ, Chen CY, Lin P. Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population. Lung Cancer. 1999;26: 27-34.
25. Hu G, Shi Z, Hu J, Zou G, Peng G, Ran P. Association between polymorphisms of microsomal epoxide hydrolase and COPD: results from meta-analyses. Respirology. 2008;13: 837-50.
26. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med. 2009;180: 618-31.
27. Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Mannervik B, Jernstrom B. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis. 1998;19: 433-6.
28. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax. 1999;54: 693-6.
29. Ishii T, Fujishiro M, Masuda M, Nakajima J, Teramoto S, Ouchi Y, Matsuse T. Depletion of glutathione S-transferase P1 induces apoptosis in human lung fibroblasts. Exp Lung Res. 2003;29: 523-36.
30. Cheng SL, Yu CJ, Yang PC. Genetic polymorphisms of cytochrome p450 and matrix metalloproteinase in chronic obstructive pulmonary disease. Biochem Genet. 2009;47: 591-601.
31. Cantlay AM, Lamb D, Gillooly M, Norrman J, Morrison D, Smith CA, Harrison DJ. Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. Clin Mol Pathol. 1995;48: M210-M14.
32. Arif E, Vibhuti A, Alam P, Deepak D, Singh B, Athar M, Pasha MA. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta. 2007;382: 37-42.
33. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350: 630-3.
34. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB. Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999;8: 283-7.
35. Song N, Tan W, Xing D, Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis. 2001;22: 11-6.
36. Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, Spitz MR. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev. 1998;7: 13-8.